Redmoor – Continuation of High-Grade Tungsten and Identification of High-Grade Tin Zones
Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel medicines for high-burden central nervous system (‘CNS’) disorders, announces that it has received a Notice of Allowance (the ‘Allowance’) from the United States Patent and Trademark Office (‘USPTO’) for a series of compounds within its proprietary SVN-SDN-14 Post-Traumatic Stress Disorder (‘PTSD’) discovery programme. One […]Read More




















